Summary
- Boston Scientific has announced an agreement to acquire Augmenix for up to $600 million.
- Augmenix has developed a hydrogel that creates a barrier between the prostate gland and the rectum during radiation treatment for prostate cancer.
- BSX is paying dearly for Augmenix' fast-growing system, which will be accretive in future years and has the potential for expansion to other indications.
Quick Take
Boston Scientific (BSX) has announced an agreement to acquire Augmenix for up to $600 million in total consideration.
Augmenix has developed a prescription injected hydrogel that serves to reduce side effects from prostate radiation therapy.
BSX is paying a premium for the SpaceOAR treatment, which will be accretive in the medium-term and will provide the potential for expansion into other indications over the longer term.
